U.S. markets close in 52 minutes

CareDx, Inc (CDNA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
91.15-0.10 (-0.11%)
As of 3:02PM EDT. Market open.

CareDx, Inc

1 Tower Place
9th Floor
South San Francisco, CA 94080
United States
415 287 2300

IndustryDiagnostics & Research
Full Time Employees456

Key Executives

NameTitlePayExercisedYear Born
Dr. Peter MaagExec. Chairman1.35M3.96M1967
Dr. Reginald SeetoPres, CEO & Director989.04kN/A1972
Ms. Sasha King M.B.A.Chief Marketing Officer668.8k1.63M1986
Mr. Marcel KonradVP & Corp. Controller437.53k77.54k1976
Mr. Ankur DhingraChief Financial OfficerN/AN/A1976
Mr. Paul CiccolellaSr. VP of Global OperationsN/AN/AN/A
Mr. Amitabh ShuklaSr. VP of TechnologyN/AN/AN/A
Mr. Martyn EdneySr. VP of HRN/AN/AN/A
Dr. Sham Dholakia DPHIL, M.D.Sr. VP of Medical Affairs & Clinical OperationsN/AN/AN/A
Mr. Kashif RathoreSr. VP of Digital Bus.N/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It offers AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; and AlloSure Heart, a dd-cfDNA test to identify underlying cell injury leading to organ rejection. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; Olerup SBT, a product range for sequence-based typing of HLA alleles; QTYPE that enables precision in HLA typing at a low to intermediate resolution for samples that uses real-time polymerase chain reaction methodology; and TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Ottr, a transplant patient tracking software; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors. CareDx, Inc. has a license agreement with Illumina, Inc. for the distribution, development and commercialization rights to NGS products and technologies; and Cibiltech SAS to commercialize KidneyCare iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. CareDx, Inc. was incorporated in 1998 and is headquartered in South San Francisco, California.

Corporate Governance

CareDx, Inc’s ISS Governance QualityScore as of June 1, 2021 is 10. The pillar scores are Audit: 6; Board: 9; Shareholder Rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.